Media Coverage

US biotech to develop canine joint candidate

Apr 21, 2017 - Animal Pharm
By Sian Lazell
Animal Pharm
April 21,2017

US biotechnology firm Myos Rens has agreed a collaborative study to investigate the use of its product candidate Fortetropin in reducing muscle loss in dogs after joint surgery.

The study will be carried out in partnership with the Kansas State University (KSU) College of Veterinary Medicine to look at the impact of Fortetropin in reducing muscle loss in dogs after tibial-plateau-leveling osteotomy (TPLO) – ligament tear repair – surgery.

TPLO surgery is commonly needed in large dogs such as Labrador Retrievers to stabilize the stifle joint after ruptures of the cranial cruciate ligament (CCL). The CCL is analogous to the anterior cruciate ligament in humans.

Fortetropin is a bioactive, proteo-lipid complex consisting of around 250 proteins, 50 lipids, peptides and other bioactive molecules that are isolated at a specific stage of development from fertilized egg yolk.

The bio-nutritional supplement Fortetropin is Myos Rens' flagship functional food product for humans. Myos Rens claims it is the first natural, clinically-proven myostatin-reducing ingredient made for human consumption.

Dr Neerav Padliya, vice president of research alliances at Myos Rens, said: "We are excited to be working with the College of Veterinary Medicine at KSU, one of the leading veterinary colleges in the US, to explore the utility of Fortetropin in animal health for the first time. Reducing muscle atrophy in dogs following orthopedic surgery is an area of unmet need."

Kenneth Harkin, professor of internal medicine at KSU, said: "Rehabilitation after TPLO surgery, essentially increasing the muscle mass that stabilizes the cruciate deficient knee, has been shown to improve mobility and decrease arthritic changes.

"Fortetropin, by naturally reducing myostatin levels, offers an innovative approach to rehabilitation that is convenient and accessible to all pet owners. We hope this will be the first of many studies that evaluate the potential benefits of Fortetropin in companion animals."

The decrease in arthritic changes mentioned by Prof Harkin could mean Fortetropin has a good chance as a product in the companion animal market. Arthritis is a common condition in older dogs, certain breeds and those that are overweight.

Various animal health firms are working on different types of treatments for canine osteoarthritis. In November, VetStem Biopharma revealed the results of research into stem cell therapy for the condition. More recently, industry leader Zoetis acquired Nexvet Biopharma for around $85 million – a move which has seen it gain access to candidates for osteoarthritis in both cats and dogs.

Reprinted with permission of Animal Pharm News




News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum